Jacobs Levy Equity Management
IPSC icon

Jacobs Levy Equity Management’s Century Therapeutics IPSC Stock Holding History

Jacobs Levy Equity Management’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,583
Closed -$27K – 1001
2024
Q2 		$27K Sell
10,583
-283,358
-96% -$896K ﹤0.01% 946
2024
Q1 		$1.23M Buy
293,941
+192,915
+191% +$817K 0.01% 678
2023
Q4 		$335K Sell
101,026
-70,256
-41% -$128K ﹤0.01% 877
2023
Q3 		$343K Sell
171,282
-11,942
-7% -$31.8K ﹤0.01% 865
2023
Q2 		$579K Sell
183,224
-139,268
-43% -$449K ﹤0.01% 794
2023
Q1 		$1.12M Buy
322,492
+198,496
+160% +$872K 0.01% 681
2022
Q4 		$636K Buy
+123,996
New +$1.17M ﹤0.01% 748

Other funds holding IPSC

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Jacobs Levy Equity Management's IPSC Position: Q3 2024 in Review

Jacobs Levy Equity Management sold out of Century Therapeutics (IPSC) in Q3 2024, closing a stake of 10,583 shares — an estimated $27K sold.

Jacobs Levy Equity Management first reported a position in IPSC in Q4 2022 and held it in 7 quarters. The position peaked at $1.23M in Q1 2024. 67 funds tracked by Wall St. Rank hold IPSC as of Q3 2024.

  • Jacobs Levy Equity Management reported no remaining Century Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 10,583 Century Therapeutics shares in Q3 2024, an estimated $27K.
  • Jacobs Levy Equity Management first reported a position in Century Therapeutics in Q4 2022 and held it in 7 quarters.
  • Jacobs Levy Equity Management's Century Therapeutics position peaked at $1.23M in Q1 2024.
  • 67 funds tracked by Wall St. Rank held Century Therapeutics as of Q3 2024.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2024, filed 14 Nov 2024.